head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2023, vol. 29, issue3
Subject Area: Medicine
DOI: 10.5272/jimab.2023293.5045
Published online: 28 July 2023

Original article
J of IMAB. 2023 Jul-Sep;29(3):5045-5048
Biser K. BorisovORCID logoCorresponding Autoremail, Vanya T. VasilevaORCID logo,
Department of Nephrology and Dialysis, Faculty of Medicine, Medical University, Pleven, Bulgaria.

Purpose: Catheter-related infections and thrombosis are the most common complications associated with the use of tunneled hemodialysis catheters.
The aim of our study was to determine the incidence of these complications in patients who underwent "locking" of their tunneled catheters and compare the cost of different options with their effect.
Materials and Methods: The study was conducted in the period 01.10.2021 - 31.03.2022. Twenty-three men and twenty-two women with a mean age of 60.82 (+/-13.629) years were randomly divided into three groups of 15 (fifteen) people each. Group A – catheter locking with TauroLock™ only, group B – with gentamicin and heparin; group C – with TauroLock™ for three months, then with heparin and gentamicin for the next three months.
Results: The median duration for tunneled catheters was 8,105 catheter-days. One complication was reported in each of the three groups. Reported costs for patients treated with TauroLock™ were calculated at 3 EUR/each dialysis session and for patients treated with gentamicin and heparin – 0.88 EUR/dialysis session.
Conclusion: The data from our study unequivocally support the thesis that locking the catheter with a TauroLock™ is comparable to the effect of the solution containing an antibiotic and anticoagulant.

Keywords: hemodialysis, catheter-related infections and dysfunction, catheter lock solutions, TauroLock™, management of tunneled catheter,

pdf - Download FULL TEXT /PDF 664 KB/
Please cite this article as: Borisov BK, Vasileva VT. Hemodialysis tunneled catheters lock with TauroLock™ versus a combination of gentamycine and heparine. J of IMAB. 2023 Jul-Sep;29(3):5045-5048. [Crossref - 10.5272/jimab.2023293.5045]

Corresponding AutorCorrespondence to: Biser Borisov, MD, PhD. Department of Nephrology and Dialysis, Faculty of Medicine, Medical University, Pleven; 8A, George Kochev str., 5800 Pleven, Bulgaria; E-mail: biserugo@abv.bg

1. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000 Mar 7;132(5):391-402. [PubMed]
2. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections. Clin Infect Dis. 2011 May;52(9):1087-99.  [PubMed]
3. United States Renal Data System 1999 Annual Data Report: part VI - Causes of death. Am J Kidney Dis. 1999 Aug;34(2, Suppl 1):S87-S94. [Internet]
4. Oliver MJ. Acute dialysis catheters. Semin Dial. 2001 Nov-Dec;14(6):432-5. [PubMed ]
5. Saxena AK, Panhotra BR. Haemodialysis catheter-related bloodstream infections: current treatment options and strategies for prevention. Swiss Med Wkly. 2005 Mar 5;135(9-10):127-38. [PubMed]
6. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. 2001 Feb;136(2):229-34. [PubMed]
7.Vascular Access Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis. 2006 Jul;48 Suppl 1:S248-73. [PubMed]
8.Banerjee S. Dialysis catheters and their common complications: an update. ScientificWorldJournal. 2009 Nov 18;9:1294-9. [PubMed]
9. Soi V, Moore CL, Kumbar L, Yee J. Prevention of catheter-related bloodstream infections in patients on hemodialysis: challenges and management strategies. Int J Nephrol Renovasc Dis. 2016 Apr 18;9:95-103. [PubMed]
10.Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020 Apr;75(4 Suppl 2):S1-S164. [PubMed]
11. Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008 Jul 29;8:102. [PubMed]
12.Winnicki W, Herkner H, Lorenz M, Handisurya A, Kikić Ž, Bielesz B et al. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. Kidney Int. 2018 Mar;93(3): 753-760. [PubMed]
13. Gudiol C, Nicolae S, Royo-Cebrecos C, Aguilar-Guisado M, Montero I, Martín-Gandul C, et al. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT). Trials. 2018 May 2;19(1):264. [PubMed]
14. Pittiruti M, Bertoglio S, Scoppettuolo G, Biffi R, Lamperti M, Dal Molin A, et al. Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus. J Vasc Access. 2016 Nov 2;17(6):453-464. [PubMed]
15. Murray E, Deighan C, Geddes C, Thomson PC. Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteraemia rates in haemodialysis patients. QJM. 2014 Dec;107(12):995-1000. [PubMed]
16. Fontseré N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, et al. Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients. Antimicrob Agents Chemother. 2014 Jul;58(7):4180-4. [PubMed]
17. Labriola L, Jadoul M. Taurolidine-based lock solutions for hemodialysis catheters: the enthusiasm should be tempered. Kidney Int. 2018 Apr;93(4):1015-1016. [PubMed]
18. Bueloni TNV, Marchi D, Caetano C, de Souza Cavalcante R, Mendes Amaral ML. Ponce D. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial. Int J Infect Dis. 2019 Aug;85:16-21. [PubMed]
19. Filiopoulos V, Hadjiyannakos D, Koutis I, Trompouki S, Micha T, Lazarou D, et  Approaches to Prolong the Use of Uncuffed Hemodialysis Catheters: Results of a Randomized Trial. Am J Nephrol. 2011; 33(3):260-8. [PubMed]
20.Wang Y, Sun X. Reevaluation of lock solutions for Central venous catheters in hemodialysis:a narrative review. Ren Fail. 2022 Dec;44(1):1501-1518. [PubMed]
21. Padilla-Orozco M, Mendoza-Flores L, Herrera-Alonso A, Garza González E, Gutiérrez Ferman JL, Rodríguez-López JM, et al. Generalized and prolonged use of gentamicin-lock therapy reduces hemodialysis catheter-related infections due to gram negatives. Nephron. 2019; 143(2):86–91. [PubMed]
22. Daoud DC, Wanten G, Joly F. Antimicrobial Locks in Patients Receiving Home Parenteral Nutrition. Nutrients. 2020 Feb 10;12(2):439. [PubMed].

Received: 12 February 2023
Published online: 28 July 2023

back to Online Journal